Skip to main content

Table 1 Baseline characteristics of included patients (stratified by survival status to day 28)

From: Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial

 

Survivor

(N = 387, 75.7%)

Non-survivor

(N = 124, 24.3%)

p-value

Log baseline IL-18

6.71 (0.91)

7.06 (1.0)

 < 0.001

Age (years)

51.51 (15.9)

59.40 (16.8)

 < 0.001

Baseline APACHE II scorea

17.95 (6.5)

21.87 (6.3)

 < 0.001

Body mass index

27.4 (6.9)

26.7 (6.5)

0.31

Pre-randomisation P/F ratio (kPa)

17.41 (7.27)

16.14 (7.14)

0.05

Sepsis—N (%)

287 (74.2)

99 (79.8)

0.20

Vasopressor use—N (%)

237 (61.2)

95 (76.6)

0.002

  1. Data presented as mean (standard deviation) unless otherwise stated
  2. APACHE: Acute physiology and chronic health evaluation
  3. aData missing in 58 patients